世界の心不全治療薬市場2020-2025:ACEI、アンジオテンシンII受容体拮抗薬、ARNI、ベータ遮断薬、アルドステロン拮抗薬、利尿薬

LP Informationが発行した調査報告書(LPI20DE1766)
◆英語タイトル:Global Heart Failure Drugs Market Growth 2020-2025
◆商品コード:LPI20DE1766
◆発行会社(リサーチ会社):LP Information
◆発行日:2020年12月(※2024年版があります。お問い合わせください。)
◆ページ数:166
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

「心不全治療薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、ACEI、アンジオテンシンII受容体拮抗薬、ARNI、ベータ遮断薬、アルドステロン拮抗薬、利尿薬など、用途別には、駆出率低下、駆出率維持などに区分してまとめた調査レポートです。心不全治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・心不全治療薬の世界市場概要(サマリー)
・心不全治療薬の企業別販売量・売上
・心不全治療薬の企業別市場シェア
・心不全治療薬の世界市場規模 2015年-2020年:種類別(ACEI、アンジオテンシンII受容体拮抗薬、ARNI、ベータ遮断薬、アルドステロン拮抗薬、利尿薬)
・心不全治療薬の世界市場規模 2015年-2020年:用途別(駆出率低下、駆出率維持)
・心不全治療薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・心不全治療薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・心不全治療薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・心不全治療薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・心不全治療薬市場の成長要因・課題・動向
・心不全治療薬の世界市場予測 2021年-2025年
・心不全治療薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・心不全治療薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・心不全治療薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・心不全治療薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・心不全治療薬の世界市場予測:種類別(ACEI、アンジオテンシンII受容体拮抗薬、ARNI、ベータ遮断薬、アルドステロン拮抗薬、利尿薬)
・心不全治療薬の世界市場予測:用途別(駆出率低下、駆出率維持)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Heart Failure Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Heart Failure Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Heart Failure Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Heart Failure Drugs, covering the supply chain analysis, impact assessment to the Heart Failure Drugs market size growth rate in several scenarios, and the measures to be undertaken by Heart Failure Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
ACEI
Angiotensin II Receptor Blockers
ARNIs
Beta Blockers
Aldosterone Antagonists
Diuretics
The proportion of ARNIs in 2018 is about 19%.

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Reduced Ejection Fraction
Preserved Ejection Fraction
The most proportion of heart failure drugs is reduced ejection fraction and the sales proportion is 69%.

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Novartis
Sun Pharma
Pfizer
Hikma
Teva
AstraZeneca
Amgen
Cipla
Roche
Merck & Co.
Mylan

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Heart Failure Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Heart Failure Drugs market by identifying its various subsegments.
Focuses on the key global Heart Failure Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Heart Failure Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Heart Failure Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Heart Failure Drugs Consumption 2015-2025
2.1.2 Heart Failure Drugs Consumption CAGR by Region
2.2 Heart Failure Drugs Segment by Type
2.2.1 ACEI
2.2.2 Angiotensin II Receptor Blockers
2.2.3 ARNIs
2.2.4 Beta Blockers
2.2.5 Aldosterone Antagonists
2.2.6 Diuretics
2.3 Heart Failure Drugs Consumption by Type
2.3.1 Global Heart Failure Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Heart Failure Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Heart Failure Drugs Sale Price by Type (2015-2020)
2.4 Heart Failure Drugs Segment by Application
2.4.1 Reduced Ejection Fraction
2.4.2 Preserved Ejection Fraction
2.5 Heart Failure Drugs Consumption by Application
2.5.1 Global Heart Failure Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Heart Failure Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Heart Failure Drugs Sale Price by Type (2015-2020)

3 Global Heart Failure Drugs by Company
3.1 Global Heart Failure Drugs Sales Market Share by Company
3.1.1 Global Heart Failure Drugs Sales by Company (2018-2020)
3.1.2 Global Heart Failure Drugs Sales Market Share by Company (2018-2020)
3.2 Global Heart Failure Drugs Revenue Market Share by Company
3.2.1 Global Heart Failure Drugs Revenue by Company (2018-2020)
3.2.2 Global Heart Failure Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Heart Failure Drugs Sale Price by Company
3.4 Global Heart Failure Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Heart Failure Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Heart Failure Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Heart Failure Drugs by Regions
4.1 Heart Failure Drugs by Regions
4.2 Americas Heart Failure Drugs Consumption Growth
4.3 APAC Heart Failure Drugs Consumption Growth
4.4 Europe Heart Failure Drugs Consumption Growth
4.5 Middle East & Africa Heart Failure Drugs Consumption Growth

5 Americas
5.1 Americas Heart Failure Drugs Consumption by Countries
5.1.1 Americas Heart Failure Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Heart Failure Drugs Value by Countries (2015-2020)
5.2 Americas Heart Failure Drugs Consumption by Type
5.3 Americas Heart Failure Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Heart Failure Drugs Consumption by Regions
6.1.1 APAC Heart Failure Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Heart Failure Drugs Value by Regions (2015-2020)
6.2 APAC Heart Failure Drugs Consumption by Type
6.3 APAC Heart Failure Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Heart Failure Drugs by Countries
7.1.1 Europe Heart Failure Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Heart Failure Drugs Value by Countries (2015-2020)
7.2 Europe Heart Failure Drugs Consumption by Type
7.3 Europe Heart Failure Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Heart Failure Drugs by Countries
8.1.1 Middle East & Africa Heart Failure Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Heart Failure Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Heart Failure Drugs Consumption by Type
8.3 Middle East & Africa Heart Failure Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Heart Failure Drugs Distributors
10.3 Heart Failure Drugs Customer

11 Global Heart Failure Drugs Market Forecast
11.1 Global Heart Failure Drugs Consumption Forecast (2021-2025)
11.2 Global Heart Failure Drugs Forecast by Regions
11.2.1 Global Heart Failure Drugs Forecast by Regions (2021-2025)
11.2.2 Global Heart Failure Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Heart Failure Drugs Forecast by Type
11.8 Global Heart Failure Drugs Forecast by Application

12 Key Players Analysis
12.1 Novartis
12.1.1 Company Information
12.1.2 Heart Failure Drugs Product Offered
12.1.3 Novartis Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Novartis Latest Developments
12.2 Sun Pharma
12.2.1 Company Information
12.2.2 Heart Failure Drugs Product Offered
12.2.3 Sun Pharma Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Sun Pharma Latest Developments
12.3 Pfizer
12.3.1 Company Information
12.3.2 Heart Failure Drugs Product Offered
12.3.3 Pfizer Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Pfizer Latest Developments
12.4 Hikma
12.4.1 Company Information
12.4.2 Heart Failure Drugs Product Offered
12.4.3 Hikma Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Hikma Latest Developments
12.5 Teva
12.5.1 Company Information
12.5.2 Heart Failure Drugs Product Offered
12.5.3 Teva Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Teva Latest Developments
12.6 AstraZeneca
12.6.1 Company Information
12.6.2 Heart Failure Drugs Product Offered
12.6.3 AstraZeneca Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 AstraZeneca Latest Developments
12.7 Amgen
12.7.1 Company Information
12.7.2 Heart Failure Drugs Product Offered
12.7.3 Amgen Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Amgen Latest Developments
12.8 Cipla
12.8.1 Company Information
12.8.2 Heart Failure Drugs Product Offered
12.8.3 Cipla Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Cipla Latest Developments
12.9 Roche
12.9.1 Company Information
12.9.2 Heart Failure Drugs Product Offered
12.9.3 Roche Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Roche Latest Developments
12.10 Merck & Co.
12.10.1 Company Information
12.10.2 Heart Failure Drugs Product Offered
12.10.3 Merck & Co. Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Merck & Co. Latest Developments
12.11 Mylan
12.11.1 Company Information
12.11.2 Heart Failure Drugs Product Offered
12.11.3 Mylan Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Mylan Latest Developments

13 Research Findings and Conclusion



【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の心不全治療薬市場2020-2025:ACEI、アンジオテンシンII受容体拮抗薬、ARNI、ベータ遮断薬、アルドステロン拮抗薬、利尿薬(Global Heart Failure Drugs Market Growth 2020-2025)]についてメールでお問い合わせはこちらでお願いします。